|Trade names||Emilace (JP)|
|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||387.91 g·mol−1|
|3D model (JSmol)|
Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|